Evidence map›Paper›PMID 40375336›Full record

ArticleRespiratory research2025

Angiotensin receptor blockers use and lung cancer risk in Chinese patients with chronic obstructive pulmonary disease: a population-based cohort study.

Wenhao Li, Qingqing Yang, Yahong Chen, Yexiang Sun, Peng Shen, Feng Sun, Jinzhu Jia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenhao LiDepartment of Biostatistics, School of Public Health, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China.
Qingqing YangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China.
Yahong ChenDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Yexiang SunYinzhou District Center for Disease Control and Prevention, Ningbo, Zhejiang, China.
Peng ShenYinzhou District Center for Disease Control and Prevention, Ningbo, Zhejiang, China.
Feng SunDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China. sunfeng@bjmu.edu.cn.
Jinzhu JiaDepartment of Biostatistics, School of Public Health, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China. jzjia@math.pku.edu.cn.

Funding

National Natural Science Foundation of China 72474008Special Project for Director, China Center for Evidence-Based Traditional Chinese Medicine 2020YJSZX-2the third batch of Key Projects of Scientific Act for Drug Regulation of China RS2024X006
6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is one of the most prevalent specific chronic respiratory diseases. It could worsen the development of cardiovascular diseases (CVD) and lung cancer. We aimed to elucidate the relationship between the use of angiotensin receptor blockers (ARBs) and the incidence of lung cancer among the COPD population in China.

methodsThis retrospective cohort included COPD patients identified by the international classification of diseases 10th edition (ICD-10) codes in the Yinzhou Regional Health Care Database. The use of ARBs was defined according to the use and cumulative use. The lung cancer was defined by ICD-10 code (up to 2023). Time-varying Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of the use of ARBs on the risk of lung cancer.

resultsThis population-based COPD cohort comprised 25,436 patients with an average age of 68.2 years (standard deviation [SD]: 12.59 years), of which 60.6% were male. A total of 8,611 patients received at least one prescription for ARBs. After adjusting for multiple covariates, the results showed that cumulative annual exposure to ARBs was associated with a reduced risk of lung cancer (HR: 0.93, 95% CI: 0.90-0.97). The results of sensitivity analyses and negative control exposure analyses indicated that the associations were largely consistent and less likely to be influenced by unobserved confounding.

conclusionsThe use of ARBs may reduce the risk of lung cancer among patients with COPD.

Indexed as

Angiotensin Receptor AntagonistsLung NeoplasmsPopulation SurveillancePulmonary Disease, Chronic ObstructiveAgedAged, 80 and overChinaCohort StudiesEast Asian PeopleFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsAngiotensin Receptor AntagonistsAngiotensin receptor blockersChronic obstructive pulmonary diseaseCohort studyLung cancer

Identifiers

PMID40375336
PMCPMC12083003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.